8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Feb 26, 2026·SEC
Material company update
Jan 8, 2026·SEC
Entrada Therapeutics, Inc.(TRDA)Earnings, Financials & Key Ratios
TRDA•NASDAQ
$7.74
Price updated Jun 27, 2026
AboutEntrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.Show more
- Revenue$25M-87.9%
- EBITDA-$156M-406.3%
- Net Income-$144M-319.0%
- EPS (Diluted)-3.47-306.5%
- Gross Margin83.89%-16.1%
- EBITDA Margin-611.99%-2640.1%
- Operating Margin-613.66%-2851.4%
- Net Margin-565.48%-1916.2%
- ROE-39.13%-300.0%
TRDA Price & Volume
Entrada Therapeutics, Inc. (TRDA) stock price & volume — 10-year historical chart
Loading chart...
Milestone Dependency Masks Structural Cash Burn Risks
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Adequate
Cash Flow:Burning
Primary Risk:Clinical milestone funding dependency
Key Thesis Takeaways
- Entrada Therapeutics faces a precarious financial outlook as its revenue model remains entirely dependent on episodic collaboration milestones, which have plummeted by 95.7% year-over-year as of 2026Q1.
- The company's reliance on a high-cost R&D structure, consistently exceeding $30 million per quarter, continues to erode its asset base, which has contracted from $582.0 million in 2024Q2 to $335.5 million in 2026Q1.
- Investors should monitor the exhaustion of deferred revenue, which fell from $157.9 million in 2024Q1 to just $254.0 thousand in 2026Q1, as this signals an urgent need for new capital to sustain the EEV platform development.
Verdict Logic
the company's inability to generate recurring revenue, evidenced by the 95.7% revenue contraction in 2026Q1, combined with a $41.7 million quarterly cash burn, suggests significant dilution risk for shareholders.
TRDA Growth Metrics
Entrada Therapeutics, Inc. (TRDA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-96.67%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-770.34%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-596.09%
Return on Capital
10 Years-37.19%
5 Years-18.68%
3 Years-8.84%
Last Year-37.15%
TRDA Recent Earnings
Entrada Therapeutics, Inc. (TRDA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.95+10.4%
$1.06
Rev
$875,000-70.0%
$3M
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$0.94+28.8%
$1.32
Rev
$1M-82.5%
$7M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$1.06-1.9%
$1.04
Rev
$2M-81.0%
$8M
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$1.04-20.9%
$0.86
Rev
$2M-75.1%
$8M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.95vs $1.06+10.4% | $875,000vs $3M-70.0% |
| Q1 2026 | Feb 26, 2026 | $0.94vs $1.32+28.8% | $1Mvs $7M-82.5% |
| Q4 2025 | Nov 6, 2025 | $1.06vs $1.04-1.9% | $2Mvs $8M-81.0% |
| Q3 2025 | Aug 6, 2025 | $1.04vs $0.86-20.9% | $2Mvs $8M-75.1% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Entrada Therapeutics, Inc. (TRDA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $7.74 | $300.47M | -2.23 | -87.94% | -565.48% | -39.13% | — | |
| $78.89 | $11.11B | -6466.39 | 23258.15% | -48.38% | -55.09% | — | |
| $16.68 | $1.87B | -4.38 | 16.92% | -597.04% | -57.27% | — | |
| $34.81 | $3.58B | -42.98 | 120.01% | -49.17% | -5.89% | — | |
| $2.85 | $279.03M | -1.58 | 25.39% | -281.59% | -677.39% | — | |
| $54.92 | $5.3B | -8.49 | -89.97% | -13856.54% | -30.88% | — |
Compare TRDA vs Peers
Entrada Therapeutics, Inc. (TRDA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TRDA SEC Filings & Documents
Entrada Therapeutics, Inc. (TRDA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when TRDA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
TRDA Frequently Asked Questions
Entrada Therapeutics, Inc. (TRDA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Entrada Therapeutics, Inc.'s revenue?
Entrada Therapeutics, Inc. (TRDA) reported $5.7M in revenue for fiscal year 2025.
How fast is Entrada Therapeutics, Inc. growing?
Entrada Therapeutics, Inc. (TRDA) saw revenue decline by 87.9% over the past year.
Is TRDA profitable?
Entrada Therapeutics, Inc. (TRDA) reported a net loss of $166.1M for fiscal year 2025.
Dividend & Returns
What is TRDA's return on equity?
Entrada Therapeutics, Inc. (TRDA) has a return on equity (ROE) of -39.1%. Negative ROE indicates the company is unprofitable.
What is Entrada Therapeutics, Inc.'s free cash flow?
Entrada Therapeutics, Inc. (TRDA) had negative free cash flow of $131.6M in fiscal year 2025, likely due to heavy capital investments.